Literature DB >> 1774441

Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.

A N Gam1, G F Jensen, K Hasselstrøm, M Olsen, K S Nielsen.   

Abstract

The statement that pituitary hyperthyroidism reflects peripheral hyperthyroidism is still controversial. To evaluate a possible relationship between the calcium and the thyroid metabolism, 29 women with thyroxine (T4) substituted hypothyroidism were examined. They were separated into two groups, one with normal (0.15 to 6 mU/l) and one with suppressed TSH (less than 0.15 mU/l). All the women were judged euthyroid both by their T4 and T3 and by their clinics. The daily dose of T4 (median 0.15 mg in both groups) had been unchanged and TSH level had been stable during the previous six months. Bone mineral content (BMC) of the lumbar spine, bone mineral density (BMD) of left and right collum femoris, serum alkaline phosphatase activity (AP), serum concentration of osteocalcin (Ost) and urinary excretion of hydroxyproline/creatine (Hpr/crea) were similar in the two groups. Furthermore, sex- hormone-binding-globulin (SHBG) was equal in the two groups, but significantly higher than in normals (p less than 0.01). A significant positive correlation was found between serum Ost and Hpr/crea (p less than 0.05) indicating a balanced state where bone formation equals bone resorption. AP failed to correlate to Ost and Hpr/crea because the AP raises from both bone and liver of bone and liver metabolism whereas the two others predominantly reflect bone metabolism. SHBG, being a marker of liver metabolism, was elevated in both groups, probably because of the oral administration of T4. Our data suggest that euthyroid, T4 substituted patients have a normal calcium metabolism whether TSH levels are suppressed or not.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774441     DOI: 10.1007/BF03346838

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.

Authors:  T L Paul; J Kerrigan; A M Kelly; L E Braverman; D T Baran
Journal:  JAMA       Date:  1988-06-03       Impact factor: 56.272

2.  Hyperthyroidism and calcium metabolism.

Authors:  D A Smith; S A Fraser; G M Wilson
Journal:  Clin Endocrinol Metab       Date:  1973-07

3.  Osteoporosis and fractures following thyrotoxicosis.

Authors:  S A Fraser; J B Anderson; D A Smith; G M Wilson
Journal:  Lancet       Date:  1971-05-15       Impact factor: 79.321

4.  Bone mineral density and thyroid hormone therapy.

Authors:  C Ribot; F Tremollieres; J M Pouilles; J P Louvet
Journal:  Clin Endocrinol (Oxf)       Date:  1990-08       Impact factor: 3.478

5.  Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic L-thyroxine treatment.

Authors:  E Nyström; P A Lundberg; K Petersen; C Bengtsson; G Lindstedt
Journal:  Clin Endocrinol (Oxf)       Date:  1989-08       Impact factor: 3.478

6.  Non-invasive evaluation of bone formation: measurements of serum alkaline phosphatase, whole body retention of diphosphonate and serum osteocalcin in metabolic bone disorders and thyroid disease.

Authors:  L Hyldstrup; I Clemmensen; B A Jensen; I Transbøl
Journal:  Scand J Clin Lab Invest       Date:  1988-11       Impact factor: 1.713

7.  Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.

Authors:  L Mosekilde; F Melsen; J P Bagger; O Myhre-Jensen; N Schwartz Sorensen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-07

8.  Bone Gla protein and sex hormone-binding globulin in nontoxic goiter: parameters for metabolic status at the tissue level.

Authors:  J Faber; H Perrild; J S Johansen
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

9.  Clinical usefulness of a highly sensitive enzyme-immunoassay of TSH.

Authors:  T Mori; H Imura; S Bito; K Ikekubo; S Inoue; S Hashida; E Ishikawa; H Ogawa
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

10.  Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment.

Authors:  B Krølner; J V Jørgensen; S P Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  1983-05       Impact factor: 3.478

View more
  4 in total

1.  Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial.

Authors:  Christian Meier; Müller Beat; Merih Guglielmetti; Mirjam Christ-Crain; Jean-Jacques Staub; Marius Kraenzlin
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

2.  Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer.

Authors:  C Regalbuto; C Alagona; R Maiorana; R Di Paola; M Cianci; G Alagona; S Sapienza; R Vigneri; V Pezzino
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

3.  Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.

Authors:  F Hawkins; D Rigopoulou; K Papapietro; M B Lopez
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

Review 4.  Thyroid Hormone Diseases and Osteoporosis.

Authors:  Alessandro P Delitala; Angelo Scuteri; Carlo Doria
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.